Clinical translation in the virtual liver network

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 7, 2014, Pages

  Kuepfer, L ^a   Kerb, R ^b   Henney, A M ^c  

^a BAYER AG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

XENOBIOTIC AGENT;

CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG METABOLISM; HUMAN; INTEGRATION; LIVER; LIVER BLOOD FLOW; NONHUMAN; PATIENT SAFETY; PHARMACOKINETICS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; TRANSLATIONAL RESEARCH; VIRTUAL LIVER NETWORK;

EID: 84905367213     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.25     Document Type: Review

References (10)

1. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
2. Meyer, M., Schneckener, S., Ludewig, B., Kuepfer, L. & Lippert, J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab. Dispos. 40, 892-901 (2012).
3. Lippert, J. et al. A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst. Pharmacol. 1, e13 (2012).
4. Meyer, U.A., Zanger, U.M. & Schwab, M. Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53, 475-502 (2013).s
5. Nies, A.T., Schwab, M. & Keppler, D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol. 4, 545-568 (2008).
6. Waldman, S.A., van der Graaf, P.H. & Terzic, A. Systems approaches evolve clinical pharmacology. CPT Pharmacometrics Syst. Pharmacol. 2, e68 (2013).
7. Yzet, T. et al. Dynamic measurements of total hepatic blood flow with Phase Contrast MRI. Eur. J. Radiol. 73, 119-124 (2010).
8. Eissing, T. et al. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2, 4 (2011).
9. Krauss, M. et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacol. 1, 6 (2013).
10. Ibrutinib label. Daily Med (2013).